Brusatol Inhibits Proliferation and Metastasis of Colorectal Cancer by Targeting and Reversing the RhoA/ROCK1 Pathway

Biomed Res Int. 2022 May 18:2022:7132159. doi: 10.1155/2022/7132159. eCollection 2022.

Abstract

Brusatol (BRU) is an important compound extracted from Brucea javanica oil, whose pharmacological effects are able to induce a series of biological effects, including inhibition of tumor cell growth, anti-inflammatory, antiviral, and antitumor. Currently, there are so few studies about the brusatol effects on colorectal cancer that its anticancer mechanism has not been clearly defined. In this study, we made an in-depth investigation into the brusatol effect towards the proliferation and metastasis of colon cancer and the possible mechanism. The inhibitory effect of BRU on the proliferation of colorectal cancer cells was unveiled via CCK-8 method and colony formation assay, while the inhibitory effect of BRU on migration and invasion of colorectal cancer cells was revealed by scratch assay and transwell assay. In addition, Western blot results also revealed that BRU inhibited not only the expressions of RhoA and ROCK1 but also the protein expressions of EMT-related markers e-cadherin, N-cadherin, Vimentin, MMP2, and MMP9 in colon cancer cells. Through the xenotransplantation model, our in vivo experiment further verified the antitumor effect of BRU on colon cancer cells in vitro, and the results were consistent with the protein expression trend. In conclusion, BRU may inhibit the proliferation and metastasis of colorectal cancer by influencing EMT through RhoA/ROCK1 pathway.

Publication types

  • Retracted Publication

MeSH terms

  • Cadherins
  • Cell Movement
  • Cell Proliferation
  • Colonic Neoplasms*
  • Humans
  • Neoplastic Processes
  • Quassins* / pharmacology
  • rho-Associated Kinases
  • rhoA GTP-Binding Protein

Substances

  • Cadherins
  • Quassins
  • RHOA protein, human
  • brusatol
  • ROCK1 protein, human
  • rho-Associated Kinases
  • rhoA GTP-Binding Protein